• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention is directed to a culture medium for growing Flavobacterium columnare comprising essential nutritional ingredients for the growth of bacteria and mucin or another mucus component as a supplement. The invention is also directed to a method for producing bacteriophages infecting Flavobacterium columnare, the method comprising the steps of adding Flavobacterium columnare bacterium to a sterile culture medium supplemented with mucin or another mucus component, incubating said culture medium, thereby obtaining a bacterial culture, optionally collecting the supernatant containing floating (planktonic) bacterial cells from said culture and transferring the supernatant to a new container in order to discard most of the biofilm and adding a bacteriophage infecting Flavobacterium columnare to said bacterial culture obtained from a previous step, and incubating the culture until the phage yield increases or peaks. Addition of mucin to soft-agar culture medium is proposed as an optimized technique for viral titration.
    公开号:FI20185086A1
    申请号:FI20185086
    申请日:2018-01-31
    公开日:2019-08-01
    发明作者:Lotta-Riina Sundberg；Gabriel Almeida；Elina Laanto
    申请人:Univ Of Jyvaeskylae；
    IPC主号:
    专利说明:

    Improved methods and culture media for production, quantification and isolation of bacteriophages infecting Flavobacterium columnare
    FIELD OF THE INVENTION
    The present invention relates to the fields of practical bacteriology and virology. Particularly, the present disclosure is directed to a method for producing stocks of bacteriophages infecting Flavobacterium columnare, the causative agent of columnaris disease, a serious fish disease responsible for significant economic losses in the fish farming industry. The present invention is based on a novel modified culture medium for growing Flavobacterium rendering the cells permissive to bacteriophages infecting the pathogen.
    BACKGROUND OF THE INVENTION
    The majority of antibiotics use today is from intensive farming systems connected to human food production. With the increasing number of antibiotic resistance at hand and the growing concern of associated healthcare problems, the use of antibiotics in food production is at stake due to high amount of environmental leakage. Therefore, the use of bacteriophages (phages) as a selective therapy method to destroy pathogenic bacteria is increasing. These viruses are ubiquitous in the environment, infect only bacteria and are harmless to humans and other animals.
    Columnaris disease is a significant problem for fresh water aquaculture around the world. It is caused by Flavobacterium columnare, affects the external mucosal surface of fishes, and is usually treated with antibiotics (mainly oxytetracycline). Alternative treatments are welcomed since antibiotic use can be expensive and lead to bacterial resistance. Furthermore, antibiotics do not eradicate the pathogen from the rearing environment, because as an opportunist, it can survive outside the fish host for long periods (several months). One of the alternatives for antibiotics in columnaris outbreaks is the use of F. columnare infecting phages. These organisms are specific and efficient in killing their bacterial hosts, but so far treatment efficacy has only been tested in laboratory settings. Besides, it has been difficult to isolate these viruses from the environment, and to grow them using conventional phage production techniques.
    The mucosal surfaces of fish are the environments where Flavobacterium and at least some of the infecting phages may naturally interact. Phage-mucus interaction has been proposed as a non-host derived form of mucosal immunity conserved in metazoans (Barr et al. 2013). The
    20185086 PRH 31 -01-2018 prior art describes survival of F. columnare in primary fish mucus and in formulated water containing purified porcine mucin (Staroscik and Nelson 2007; Shoemaker and LaFrentz 2015). Other authors have shown thatF columnare has a chemotactic response to primary catfish mucus and that mucus exposure improved extracellular protease activity and upregulated gliding motility gene gldH (Klesius et al. 2008; 2010; Shoemaker and LaFrentz 2015).
    One characteristic of the F. columnare infecting phages is that it is not possible to produce large quantities of them by using the conventional phage production methods based on liquid cultures. Although other methods can be used, they make the process too time consuming and 10 hard to implement in a large scale. Another common issue with Flavobacterium phages concerns quantification by titration, since very often the bacterial growth in titration plates is not optimal and the phage enumeration fails, resulting in loss of time and resources. Obtaining new phages from field samples is also crucial for research and for using these organisms in phage therapy, so improved methods for phage isolation can be beneficial. All the three points 15 above are problems that need solving before columnaris phage therapy becomes reality.
    SUMMARY OF THE INVENTION
    The culture medium and methods we propose as invention here (1) improve the production of phages capable of infecting F. columnare by hundreds to thousands fold when compared to the conventional method of phage production, (2) improve the titration of these phages on soft 20 agar cultures by making the method reproducible, and (3) makes phage isolation from field samples easier and more efficient. The present inventors have surprisingly discovered that a novel modified culture media supplemented with mucin provides all these improvements.
    The present invention is thereby directed to a culture medium for growing Flavobacterium columnare comprising essential nutritional ingredients for the growth of bacteria and mucin 25 or another mucus component as a supplement. In the present invention, the mucin supplement is responsible for creating a differentiated physiological state of virulence on the cells which also makes them more susceptible for phage infections.
    The present invention is also directed to a method for producing bacteriophages infecting Flavobacterium columnare comprising the steps of
    a) adding Flavobacterium columnare bacterium to a sterile culture medium supplemented with mucin or another mucus component,
    20185086 PRH 31 -01-2018
    b) incubating said culture medium, thereby obtaining a bacterial culture modified by mucin exposure,
    c) optionally collecting the supernatant containing floating (planktonic) bacterial cells from said culture and transferring the cells to a new container in order to discard most of the biofilm,
    d) adding a bacteriophage infecting Flavobacterium columnare to the bacterial culture obtained from step b) or c),
    e) incubating the culture obtained in step d) until the culture is ready for phage collection.
    Another aim of the present invention is to provide a use of the culture medium supplemented with mucin or another mucus component for culturing bacteria of the genus Flavobacterium.
    Another aim of the present invention is to provide a method for determining the number of plaque-forming phage particles in a bacteriophage stock or a sample comprising or suspected to comprise bacteriophages infecting Flavobacterium, the method comprising the steps of
    a) preparing a sterile semi-solid culture medium supplemented with mucin or another mucus component,
    b) adding aliquots of Flavobacterium bacterium grown in a culture medium and a dilution of the bacteriophage stock or sample to an aliquot of the semi-solid culture medium obtained in step a) and plating the mix on an agar plate or a Petri dish; or alternatively adding an aliquot of Flavobacterium columnare bacterium grown in a culture medium to an aliquot of the semi- solid culture medium obtained in step a) and plating the mix on an agar plate or a Petri dish and adding a dilution of the bacteriophage stock or sample on top of the plated mix;
    c) repeating the previous step with a different dilution of said bacteriophage stock or sample, wherein each mix is plated on a separate agar plate or Petri dish;
    d) incubating the plates obtained in steps b) and c); and
    e) determining the number of bacteriophage particles in the stock or sample by counting plaques on the plates.
    20185086 PRH 31 -01-2018
    BRIEF DESCRIPTION OF THE DRAWINGS
    Figure 1. Optimized phage production method. A) Recommended general protocol for optimized F. columnare infecting phages production. B) Example of a 5ml culture of F. columnare made in culture medium supplemented with mucin. Picture taken after 22 hours of 5 incubation (right before collecting the supernatant for making the infection). Note the long, stringy, biofilm. C) Example of a 50ml culture of F. columnare made in culture medium supplemented with mucin. Picture taken at the time of collecting the virus containing supernatant (22h of growth, plankton collected and infected for 24h). Note that the biofilm reappears during the infection. D) Example of a 400ml F. columnare made in culture medium 10 supplemented with mucin. Picture taken at the time of collecting the virus containing supernatant (22h of growth followed by 24h of infection, no separation between biofilm and plankton prior to infection). Note that a lower rotation was used to minimize biofilm detachment when using this larger volume. E) Example of phage FCL2 production on F. columnare Bl85 strain, shown as the ratio between virus yield in mucin cultures divided by 15 the yield in control cultures. F) Same as in E, but shown as the ratio between total virus yield divided by the inoculum. G) Example of phage VI56 production on F. columnare B245 strain, shown as the ratio between virus yield in mucin cultures divided by the yield in control cultures. H) Same as in G, but shown as the ratio between total virus yield divided by the inoculum. Note that the optimal moi and mucin concentration varies according to the virus20 host pair, and that virus yield is negative in control cultures.
    Figure 2. Optimized phage titration method and examples of bacterial lawns formed using soft-agar Shieh or soft-agar-mucin Shieh. A) Recommended general protocol for optimized F. columnare infecting phages titration. B) F. columnare strain B245 lawns formed on soft-agar Shieh (left) and on soft-agar-mucin Shieh (right). C) F. columnare strain B067 lawns formed 25 on soft-agar Shieh (left) and on soft-agar-mucin Shieh (right). D) F. columnare strain Bl85 lawns formed on soft-agar Shieh (left) and on soft-agar-mucin Shieh (right).
    Figure 3. Optimized phage isolation method. A) Overview of the proposed isolation protocol based on F. columnare mucin cultures. B) Example of a titration plate used for screening six different enrichment cultures.
    20185086 PRH 31 -01-2018
    DETAILED DESCRIPTION OF THE INVENTION
    The abbreviation “cfu” used below is known in the art and refers to colony-forming unit used to estimate the number of viable microbes in a sample or aliquot. The abbreviation “pfu” refers in the art to a plaque-forming unit, i.e. a measure of the number of phage particles causing lysis of the infected host cell and thus forming a plaque of dead cells within a confluent lawn of host cells. The abbreviation “moi” is also used in the art and refers to multiplicity of infection, i.e. the ratio of the number of bacteriophage or virus particles to the number of infection targets (in this case F. columnare cells).
    The term “planktonic cells” refers herein to single-cells that may float or swim in a liquid 10 medium. Planktonic cells are usually physiologically distinct from the cells of the same organism growing in a biofilm.
    Bacteriophages are a group of viruses that infect bacteria, and are thus distinct from the animal and plant viruses. Bacteriophages replicating through a lytic cycle cause lysis of the host bacterial cell as a normal part of their life cycles. The natural capability of these phages 15 to infect and kill bacteria, together with the specificity of the phage-bacterial interactions, is the basic phenomena on which the concept of phage therapy is built. Therefore, phages that possess lytic life cycle are suitable candidates for phage therapy.
    Those skilled in the art are capable of growing bacteriophage in the bacterial host using conventional methods. Bacteriophage stocks can be generated by growing the phage in a liquid medium containing the target organism, i.e. the bacterial host. Growth of bacteriophage on plates comprising a layer of a solid phase (bottom layer) and a layer of semi-solid phase (top layer) is another known procedure to one skilled in the art, wherein the phage-bacteria mixture is added to the semi-solid culture medium and the semi-solid medium is spread on a solid phase in a plate (e.g. a Petri dish). The commonly used procedure for obtaining such plates is to use an agar concentration of 0.8-1.5% to obtain the solid layer and an agar concentration of 0.7% in the semi-solid medium. Other gel-forming reagents than agar can also be used for solid and semi-solid medium. The plate method is specifically used for phage titration (i.e. the determination of the number of active phage particles in a stock) and also when localization and isolation of a specific, single bacteriophage strain from the plate is desired.
    20185086 PRH 31 -01-2018
    The aim of the present invention is to improve the production of phages capable of infecting F. columnare by providing a novel modified culture medium for growing Flavobacterium columnare, the medium comprising essential nutritional ingredients for the growth of bacteria and mucin or another mucus component, preferably purified mucin, more preferably purified porcine mucin, such as porcine type III mucin, as a supplement. The concentration of mucin in the medium is preferably 0.0001 - 1% (w/v), more preferably 0.001 - 1% (w/v), most preferably 0.01 - 0.2% (w/v).
    Mucin is the main component of mucus and its presence changes several aspects concerning how the bacteria grow and its characteristics. The present disclosure shows that the changes that occur in the mucin containing growth media also makes the bacteria more prone to viral infections and results in the increased viral yield and improved viral recovery obtained. Mucin presence is not an issue to the final phage product since it is easily removed from the system by the common virus purification procedures. The costs of producing viruses using this method are not significantly higher since the only extra ingredient needed is the mucin.
    In alternative embodiments of the invention, the culture medium of the invention can be liquid medium, solid medium, or a semi-solid medium such as a soft-agar. For scaling-up, the liquid medium is preferred. Culture media comprising essential nutritional ingredients for the growth of bacteria are well-known in the art. In an embodiment, the culture medium of the present invention comprises at least peptone and/or yeast extract to support the growth of bacteria, preferably the medium comprises the ingredients of Shieh recipe or, e.g., Reasoner’s 2A agar (R2A agar). The peptone used in the culture medium can be any water-soluble mixture of polypeptides and amino acids formed by the partial hydrolysis of a protein source. Yeast extracts comprise various forms of processed yeast products made by extracting the cell contents of the yeast cells (i.e. removing the cell walls of the yeast cells). An example of the ingredients of preferred Shieh broth/agar is as follows (adapted from Song et al., 1988): peptone (e.g. by Difco™, Detroit, Mich.), 5 g/liter; yeast extract (e.g. by Difco™), 0.5 g/liter; sodium acetate(H2O)3, 0.0166 g/liter; BaC12(H2O)2, 0.01 g/liter; K2HPO4(H2O)3, 0.132g/liter; KH2PO4, 0.05 g/liter; MgSO47H2O, 0.3 g/liter; CaCl2(H2O)2, 0.0067 g/liter; FeSO47H2O, 0.001 g/liter; NaHCCh, 0.05 g/liter; distilled water (pH 7.2), 1,000 ml, in case of agar medium, add agar 10 g/liter.
    In a preferred embodiment of the present invention, said medium is a rich medium supporting exponential growth of the bacteria. Other nutrient medium which support Flavobacterium
    20185086 PRH 31 -01-2018 columnare growth, and even mucin added to autoclaved water, can also be used since mucin is the key ingredient. In case of using pure water with mucin the bacterial growth and phage yields are not optimal, so dilution of mucin in culture medium is recommended.
    In another embodiment, the present invention is also directed to a use of the culture medium as defined above for culturing bacteria of the genus Flavobacterium. Preferably, said Flavobacterium is Flavobacterium columnare. The present invention thus enables production of bacteriophage stocks infecting Flavobacterium columnare.
    In another important embodiment, the present invention is directed to a method for producing bacteriophages infecting Flavobacterium columnare, the method comprising the steps of:
    a) adding Flavobacterium columnare bacterium to a sterile culture medium supplemented with mucin or another mucus component, preferably purified mucin,
    b) incubating said culture medium, thereby obtaining a bacterial culture modified by mucin exposure,
    c) optionally collecting the supernatant containing floating (planktonic) bacterial cells from 15 said culture and transferring the cells to a new container in order to discard most of the biofilm,
    d) adding a bacteriophage infecting Flavobacterium columnare to the bacterial culture obtained from step b) or c),
    e) incubating the culture obtained in step d) until the culture is ready for phage collection, i.e. 20 the phage yield increases or peaks.
    In order to produce a stock of bacteriophages infecting Flavobacterium columnare, the method preferably comprises a further step of
    f) preparing a bacteriophage stock from the culture obtained in step e).
    In order to perform phage titration, the method preferably comprise further steps of
    g) preparing a sterile semi-solid culture medium supplemented with mucin or another mucus component, preferably purified mucin, and
    h) adding aliquots of Flavobacterium columnare bacterium grown in a culture medium, preferably supplemented with mucin or another mucus component, and a dilution of the
    20185086 PRH 31 -01-2018 bacteriophage stock obtained in step f) to an aliquot of the semi-solid culture medium obtained in step g) and plating the mix on an agar plate or a Petri dish; or alternatively adding an aliquot of Flavobacterium columnare bacterium grown in a culture medium, preferably supplemented with mucin or another mucus component, to an aliquot of the semi-solid culture 5 medium obtained in step g) and plating the mix on an agar plate or a Petri dish and adding a dilution of the bacteriophage stock obtained in step f) on top of the plated mix; i) repeating the previous step with a different dilution of said bacteriophage stock, wherein each sample is plated on a separate agar plate or Petri dish;
    j) incubating the plates obtained in steps h) and i); and
    k) determining the number of bacteriophage particles in the stock by counting plaques on the plates.
    In a specific embodiment, the method is directed to isolation of new bacteriophage strains from environmental samples, wherein the bacteriophage infecting Flavobacterium columnare added to said bacterial culture in step d) is provided by an environmental sample such as a 15 water sample, a fish tank water sample or a fish mucus or tissue sample or by any kind of a sample known or suspected to contain Flavobacterium infecting phages such as biofilms and sediments. Enrichment cultures and phage stocks of steps e) and f) are then sampled and phage presence determined by the phage titration method described by steps g) to k).
    Obtained plaques can be collected and further purified or grown by the methods described 20 above.
    In a separate embodiment, the present disclosure is directed to a method for determining the number of plaque-forming phage particles in a bacteriophage stock or a sample comprising or suspected to comprise bacteriophages infecting Flavobacterium, the method comprising the steps of:
    a) preparing a sterile semi-solid culture medium supplemented with mucin or another mucus component,
    b) adding aliquots of Flavobacterium bacterium grown in a culture medium and a dilution of the bacteriophage stock or sample to an aliquot of the semi-solid culture medium obtained in step a) and plating the mix on an agar plate or a Petri dish; or alternatively adding an aliquot 30 of Flavobacterium columnare bacterium grown in a culture medium to an aliquot of the semi
    20185086 PRH 31 -01-2018 solid culture medium obtained in step a) and plating the mix on an agar plate or a Petri dish and adding a dilution of the bacteriophage stock or sample on top of the plated mix;
    c) repeating the previous step with a different dilution of said bacteriophage stock or sample, wherein each mix is plated on a separate agar plate or Petri dish;
    d) incubating the plates obtained in steps b) and c); and
    e) determining the number of bacteriophage particles in the stock or sample by counting plaques on the plates.
    Examples of these methods are presented in the Experimental Section below. In conclusion these methods are efficient, not expensive, can be made in larger scales and solve the problem 10 of producing phages against F. columnare at levels high enough required for phage therapy agents or phage research. The method also makes phage quantification more reliable and allows for efficient phage recovery from field samples, making it easier to obtain new phages from nature. Taking all three processes together, we propose a full optimized package with applicability for columnaris disease phage therapy products development, covering from 15 phage isolation to phage production and phage quantification. Each of these three steps has been made more efficient and reliable by our methods.
    Accordingly, the present invention also provides a kit for growing Flavobacterium columnare and phages infecting the bacteria, the kit comprising one or more containers comprising reagents for preparing a culture medium suitable for growing Flavobacterium columnare and 20 a container comprising mucin or another mucus component, preferably purified mucin such as purified porcine mucin. Preferably said reagents are selected from the group consisting of: peptone, yeast extract, minerals and vitamins. More preferably, said culture medium is Shieh medium.
    The following examples are given to further illustrate embodiments of the present invention, 25 but are not intended to limit the scope of the invention. It will be obvious to a person skilled in the art, as technology advances, that the inventive concept can be implemented in various ways. The invention and its embodiments are thus not limited to the examples described herein, but may vary within the scope of the claims.
    20185086 PRH 31 -01-2018
    EXPERIMENTAL SECTION
    Example 1. Flavobacterium columnare phage production using mucin
    1. 5x104 cfu ofF columnare strain Bl85 or B245, from a fresh overnight culture, were added to five millilitres of 0.5x Shieh supplemented with 0.1% porcine mucin. Control cultures were also prepared by adding the same amount of cells to the same volume of 0.5x Shieh cultures without the supplementation. The samples were incubated at 25 degrees Celsius under 120 rpm (80 rpm if larger volumes were used in glass flasks). The formation of a thick biofilm ring on the liquid-air interface and clear or slightly turbid liquid is a good indication of appropriate culturing conditions. Examples are shown in Figure 1.
    Mucin concentration can vary, e.g., from 1 to 0.01%. For scaling up, 104 cfu/ml can be used as inoculum. If cell number quantification is not possible, the fixed volume of 15 μΐ of a 1/100 dilution of an overnight F. columnare turbid culture can be used per 5ml of culture, with some impact to the optimal phage yield at the end.
    2. After 22 hours, a spectrophotometer was set to 595 nm and OD595 of the control cultures 15 was measured to calculate the amount of viruses to be used for infection (the OD was measured from the controls because they are more homogeneous. The mucin culture at this point had biofilm formed and clearer supernatant, so OD measurements would not have been reliable to estimate the real number of cells). Optical density to cfu conversion is calculated by a previously established standard curve.
    The incubation time can vary between 18 to 24 hours.
    3. All the supernatant from the mucin cultures was removed and transferred to a new flask or vial by pouring. This supernatant contained the planktonic cells which were infected.
    3.1. Alternatively, the original mucin culture can be used directly for viral growth in case of biofilm infecting phages.
    4. Following the step 3 or 3.1, the bacteria were infected with bacteriophage strain FCL2 (Bl85 as host) or VI56 (B245 as host) using a moi of 0.01. Moi can vary from 1 to 0.001. If cell number quantification is not possible for moi calculation, 3xl06 viruses can be added as inoculum for each 5ml of culture, with some impact to the optimal phage yield at the end.
    20185086 PRH 31 -01-2018
    5. The cultures were centrifuged (Sorvali SLA rotor, 8000rpm, at 4 degrees Celsius, 15 minutes) 24 hours after infection to remove bacterial cells, cell debris and mucin.
    Collection time can vary from 4 to 48 hours.
    6. The supernatant was collected and then followed virus purification or quantification by 5 standard protocols.
    The conditions above have been tested for FCL2-B185 and V156-B245 pairs, and may vary slightly if other bacteria or phage are used. In the case of a new or untested phage, using the proposed approach can be a good starting point but improvements can be made by changing conditions especially in steps 1 and 4, and also by comparing step 3 to 3.1 infections.
    Results and discussion
    Different approaches were used to study F. columnare and phage interactions in mucin. For all tests the FCL2-B185 phage-bacteria pair was used as models. F. columnare strain Bl85 was chosen because it has been shown to be virulent and thus relevant as a columnaris disease causing agent, while phage FCL2 has been shown before to be efficient as phage therapy tool (Laanto et al. 2011; 2015). As negative controls, we used bacterial hosts unrelated to F. columnare and its phages (Escherichia coH. Salmonella and Flavobacterium sp). in which no improvement of phage production was detected. Then the F. columnare results were validated using V156-B245 phage-host pair and other phages isolated in this study.
    Experiments were made by adding phage and bacteria at the same time to mucin cultures, 20 letting the bacteria grow first in mucin before adding the phages, testing different concentrations of Shieh media and mucin, evaluating the best time to harvest the phages, testing different amounts of viral inoculums, and infecting the full mucin cultures or separating its components (biofilm and planktonic cells) before infection.
    In the optimal conditions we were able to improve FCL2 yield by 400.000 times and VI56 yield by 7.000 times when compared to controls. It is a significant gain, especially when considering that these viruses do not grow in control liquid cultures. Actually, there is a loss in the total amount of viruses in the control cultures regardless of the inoculum used, which is only avoided if the virus growth is made on mucin cultures. So the mucin cultures not only make the production more efficient but allow it to be made by using liquid cultures, which
    20185086 PRH 31 -01-2018 would be impossible otherwise. The proposed methodology, examples of culture aspect and representative results are shown in Figure 1.
    When three new isolated F. columnare bacteriophages were tested in this general protocol, without any type of optimization, the yield improved in mucin cultures over 15.000 times for each. For fourteen other new isolates it was possible to perform virus growth in mucin cultures but no viruses were obtained from control cultures. Our data thus clearly shows that mucin presence in F. columnare cultures improves phage infections and progeny production, yielding 1000s to 100000s more viruses than in the control cultures. The process is easy to perform, reproducible, has the potential to be scaled up and is only slightly more expensive than the conventional process. Since the method is based on liquid cultures, it is convenient for large scale commercial production. All tested F. columnare strains grew similarly on mucin cultures, making this method applicable to potentially any phage that infects these bacteria.
    Example 2. Method for producing Flavobacterium columnare lawns using soft-agar15 mucin Shieh for phage titrations
    1. The culture medium was prepared by adding 0.1% (w/v) porcine mucin to the normal softagar Shieh recipe. Mucin concentration can vary from 1 to 0.001%.
    2. The medium was autoclaved (121 degrees Celsius, 15 minutes) immediately and stored at room temperature.
    3. Before using the media was melted in a microwave oven and 3 ml was pipetted to a glass vial inside a 45 degrees water bath.
    4. The vial was removed from the water bath and cooled down, then 200-300μ1 of any F. columnare strain from previously prepared fresh overnight cultures was added to the vial. A Petri dish containing normal Shieh-agar was then overlaid with the contents of the vial.
    5. The plates prepared were incubated for 2 to 3 days at room temperature for the growth of the bacterial lawns.
    The viruses to be titrated were either mixed in the 200-300μ1 volume containing the bacteria on step 4 or dropped on top of the soft-agar-mucin Shieh layer immediately after the preparation of the plates (10μ1 drops per dilution or virus sample).
    20185086 PRH 31 -01-2018
    Results and discussion
    Formation of F. columnare uniform bacterial lawn in soft agar cultures is unpredictable and sensitive to variation in culture conditions and batches of the medium used. F. columnare tends to aggregate when taken from liquid cultures for use in the process of creating the soft5 agar plates for phage titrations. That happens with most strains and prevents the bacterial lawn to form in a homogeneous way, leading to failure in the virus titration. This is frustrating and time consuming since the failure is usually detected only one or two days later, and the titration may have to be started again from the beginning.
    For this process, we have prepared soft agar Shieh media supplemented with 0.1% purified porcine mucin. The mucin was added as powder to the Shieh-agar mix, which was then autoclaved and kept at room temperature. At the time of use the soft-agar-mucin Shieh was melted in a microwave oven and 3ml were mixed with 200μ1 of an overnight grown F. columnare culture for preparing the bacterial lawns. While several plates made with soft-agar Shieh ended up with intense clumping and not formed bacterial lawns, the plates made with soft-agar-mucin Shieh had homogeneous lawns formed all the time. Several isolates, from different genotypes, were tested and behaved similarly. The proposed methodology and examples of plates are shown in Figure 2.
    We thus found out that mucin has a positive effect on the improvement of bacterial lawns used for virus titrations. By supplementing soft-agar Shieh with mucin we have solved the problem of variation in the quality of F. columnare bacterial lawns used for titrations. It is a very convenient procedure since only requires the addition of an extra ingredient to the formula, and do not need any additional step on the process of making the titration plates. It has been effective with all F. columnare strains tested so far, so it has a broad effect and applicability.
    Example 3. Method for isolating Flavobacterium columnare phages using mucin cultures
    1. AF columnare culture was prepared by adding 5,5xl04 cfu to 5,5ml of 0.5x Shieh containing 0.1% porcine mucin and incubated for 22 hours (120 rpm, 25 degrees Celsius).
    2. On the next day the culture supernatant (planktonic cells) was divided into five new tubes by adding one ml to each. The tube containing the biofilm was kept (optional).
    20185086 PRH 31 -01-2018
    3. Four ml of the isolation (i.e. environmental) samples were added to each tube (one sample per tube).
    3.1. (optional). The biofilm tube can receive a mixture of the samples (1ml each), if phages that attacks the biofilm are desired. Then it can be processed as the other samples.
    4. 200μ1 from each culture after 6, 24 and 48 hours was collected and centrifuged (10000g, 10 minutes, room temperature).
    5. 10μ1 of each collected sample is added as drops in fresh F. columnare bacterial lawns prepared with the protocol described in Example 2.
    6. The plates were incubated 2 to 3 days and checked for lysis in the bacterial lawn.
    The original cultures can be stored at 6 degrees, the aliquots taken and the collected lysis zones from bacterial lawns can be stored at -20 or -80 degrees Celsius, to be used for further characterization of the viruses. The protocol is preferably meant for testing five different samples at the same time, and can easily be adapted for screening more samples or for testing the same five samples in different bacterial hosts at the same time.
    Results and discussion
    Initially, viral recovery was tested by adding a small amount of bacteriophage FCL-2 (40pfu) to autoclaved fish tank water and using that as our isolation samples. Isolations were made in controls (Shieh only) or in Shieh supplemented with mucin, and the effect of full mucin cultures or only biofilms and planktonic cells were tested. No significant improvement in viral 20 recovery was seen in full mucin cultures or in mucin generated biofilms, but when only planktonic cells from mucin cultures were used, viral recovery was over 1.000.000 times higher 24h after infection when compared to the controls. When pure water was used instead of fish tank water, no viruses were recovered in the controls but around 5xl07 pfii were obtained in the planktonic cells cultures.
    The main conclusions are that viruses are only recovered by the conventional isolation process if tank water is present, and that using planktonic cells from mucin cultures makes viral recovery much more efficient and also allows recovery from samples not originated from fish tanks. So the method makes recovery ofF columnare phages from conventional field samples easier, and also allows testing of other types of samples.
    Based on the results above we developed an optimized protocol for isolating F. columnare phages from field samples, and tested this protocol in 18 samples obtained from fish farms. An overview of the process is shown in Figure 3. Virus recovery was satisfactory and, when compared to the standard protocol, less plates and time were needed to achieve the results. As an example: for isolating phages from five samples using four different F. columnare strains, the conventional method would have used 60 plates while this method used 12. And since the plates were prepared using the method described in Example 2, no problems with the quality of the bacterial lawns occurred, avoiding the need of repeating the samplings or losing some samples.
    20185086 PRH 31 -01-2018
    REFERENCES
    Barr, J. J., R. Auro, M. Furian, K. L. Whiteson, M. L. Erb, J. Pogliano, A. Stotland, et al. 2013. Bacteriophage adhering to mucus provide a non-host-derived immunity. Proceedings of 5 the National Academy of Sciences 110:10771-10776.
    Klesius, P. H., C. A. Shoemaker, and J. J. Evans. 2008. Flavobacterium columnare chemotaxis to channel catfish mucus. FEMS Microbiology Letters 288:216-220.
    Klesius, P. H., J. W. Pridgeon, and M. Aksoy. 2010. Chemotactic factors of Flavobacterium columnare to skin mucus of healthy channel catfish (Ictalurus punctatus). FEMS
    Microbiology Letters 310:145-151.
    Laanto, E., J. K. H. Bamford, J. J. Ravantti, and L.-R. Sundberg. 2015. The use of phage FCL-2 as an alternative to chemotherapy against columnaris disease in aquaculture. Frontiers in microbiology 6.
    Laanto, E., L.-R. Sundberg, and J. K. H. Bamford. 2011. Phage specificity of the freshwater 15 fish pathogen Flavobacterium columnare. Applied and environmental microbiology 77:78687872.
    Shoemaker, C. A., and B. R. LaFrentz. 2015. Growth and survival of the fish pathogenic bacterium, Flavobacterium columnare, in tilapia mucus and porcine gastric mucin. FEMS Microbiology Letters 362.
    Song, Y.L., Fryer, J.L., Rohovec, J.S. 1988. Comparison of Six Media for the Cultivation of Flexibacter columnaris. Fish Pathology 23:91-94.
    Staroscik, A. M., and D. R. Nelson. 2007. The influence of salmon surface mucus on the growth of Flavobacterium columnare. Journal of Fish Diseases 31:59-69.
    20185086 PRH 31 -01-2018
    权利要求:
    Claims (15)
    [1] 1. A culture medium for growing Flavobacterium columnare comprising essential nutritional ingredients for the growth of bacteria and mucin or another mucus component as a supplement.
    5
    [2] 2. The culture medium according to claim 1 comprising 0.001 - 1% (w/v) mucin.
    [3] 3. The culture medium according to claim 2 comprising 0.01 - 0.2% (w/v) mucin.
    [4] 4. The culture medium according to any one of claims 1-3, wherein said medium supports exponential growth of the bacteria.
    [5] 5. The culture medium according to any one of claims 1-4, wherein said essential nutritional 10 ingredients comprise at least peptone and/or yeast extract.
    [6] 6. The culture medium according to any one of claims 1-5, wherein said mucin is purified mucin such as purified porcine mucin.
    [7] 7. The culture medium according to any one of claims 1-6, wherein said culture medium is a liquid medium, solid medium, or a semi-solid medium such as a soft-agar.
    15
    [8] 8. Use of the culture medium according to any one of claims 1-7 for culturing
    Flavobacterium.
    [9] 9. The use according to claim 8, wherein said Flavobacterium is Flavobacterium columnare.
    [10] 10. The use according to claim 9 for producing a stock of bacteriophages infecting Flavobacterium columnare.
    20
    [11] 11. Method for producing bacteriophages infecting Flavobacterium columnare comprising the steps of
    a) adding Flavobacterium columnare bacterium to a sterile culture medium supplemented with mucin or another mucus component,
    b) incubating said culture medium, thereby obtaining a bacterial culture modified by mucin
    25 exposure,
    20185086 PRH 31 -01-2018
    c) optionally collecting the supernatant containing floating (planktonic) bacterial cells from said culture and transferring the cells to a new container in order to discard most of the biofilm,
    d) adding a bacteriophage infecting Flavobacterium columnare to the bacterial culture
    5 obtained from step b) or c),
    e) incubating the culture obtained in step d) until the culture is ready for phage collection.
    [12] 12. The method according to claim 11 comprising a further step of
    f) preparing a bacteriophage extract from the culture obtained in step e), thereby producing a stock of bacteriophages infecting Flavobacterium columnare.
    10 13. The method according to claim 12 comprising further steps of
    g) preparing a sterile semi-solid culture medium supplemented with mucin or another mucus component,
    h) adding aliquots of Flavobacterium columnare bacterium grown in a culture medium and a dilution of the bacteriophage stock obtained in step f) to an aliquot of the semi-solid culture
    [13] 15 medium obtained in step g) and plating the mix on an agar plate or a Petri dish; or alternatively adding an aliquot of Flavobacterium columnare bacterium grown in a culture medium to an aliquot of the semi-solid culture medium obtained in step g) and plating the mix on an agar plate or a Petri dish and adding a dilution of the bacteriophage stock obtained in step f) on top of the plated mix;
    20 i) repeating the previous step with a different dilution of said bacteriophage stock, wherein each mix is plated on a separate agar plate or Petri dish;
    j) incubating the plates obtained in steps h) and i); and
    k) determining the number of bacteriophage particles in the stock by counting plaques on the plates.
    25 14. The method according to any one of claims 11-13, wherein the bacteriophage infecting
    Flavobacterium columnare added to said bacterial culture in step d) is provided by an environmental sample or any sample suspected to contain bacteriophages infecting Flavobacterium columnare.
    15. Method for determining the number of plaque-forming phage particles in a bacteriophage stock or a sample comprising or suspected to comprise bacteriophages infecting
    Flavobacterium, the method comprising the steps of:
    a) preparing a sterile semi-solid culture medium supplemented with mucin or another mucus
    5 component,
    b) adding aliquots of Flavobacterium bacterium grown in a culture medium and a dilution of the bacteriophage stock or sample to an aliquot of the semi-solid culture medium obtained in step a) and plating the mix on an agar plate or a Petri dish; or alternatively adding an aliquot of Flavobacterium columnare bacterium grown in a culture medium to an aliquot of the semi-
    10 solid culture medium obtained in step a) and plating the mix on an agar plate or a Petri dish and adding a dilution of the bacteriophage stock or sample on top of the plated mix;
    c) repeating the previous step with a different dilution of said bacteriophage stock or sample, wherein each mix is plated on a separate agar plate or Petri dish;
    d) incubating the plates obtained in steps b) and c); and
    15 e) determining the number of bacteriophage particles in the stock or sample by counting plaques on the plates.
    [14] 16. A kit for growing Flavobacterium columnare, the kit comprising one or more containers comprising reagents for preparing a culture medium suitable for growing Flavobacterium columnare and a container comprising mucin or another mucus component.
    [15] 20 17. The kit according to claim 16, wherein said reagents are selected from the group consisting of: peptone, yeast extract, minerals and vitamins.
    类似技术:
    公开号 | 公开日 | 专利标题
    Pan et al.2012|Co-infection of broilers with Ornithobacterium rhinotracheale and H9N2 avian influenza virus
    Li et al.2014|Isolation and characterization of a virulent bacteriophage SPW specific for Staphylococcus aureus isolated from bovine mastitis of lactating dairy cattle
    Muniain-Mujika et al.2003|Comparative analysis of viral pathogens and potential indicators in shellfish
    Phumkhachorn et al.2010|Isolation and partial characterization of a bacteriophage infecting the shrimp pathogen Vibrio harveyi
    WO2005024005A1|2005-03-17|Novel salmonella bacteriophage and uses thereof
    Zhang et al.2018|Application of a phage in decontaminating Vibrio parahaemolyticus in oysters
    WO2008100273A1|2008-08-21|Novel listeria monocytogenes bacteriophage and uses thereof
    Christiansen et al.2016|Effect of bacteriophages on the growth of Flavobacterium psychrophilum and development of phage-resistant strains
    Michel et al.2002|Muscle infections in imported neon tetra, Paracheirodon innesi Myers: limited occurrence of microsporidia and predominance of severe forms of columnaris disease caused by an Asian genomovar of Flavobacterium columnare
    Zheng et al.2020|Isolation of virulent phages infecting dominant mesophilic aerobic bacteria in cucumber pickle fermentation
    Jiang et al.2013|Identification and characterization of Vibrio harveyi associated with diseased abalone Haliotis diversicolor
    Wang et al.2018|Characterization and genome analysis of novel phage vB_EfaP_IME195 infecting Enterococcus faecalis
    Kim et al.2019|Application of the bacteriophage pVco-14 to prevent Vibrio coralliilyticus infection in Pacific oyster | larvae
    Rahimi-Midani et al.2020|Potential use of newly isolated bacteriophage as a biocontrol against Acidovorax citrulli
    Luo et al.2021|Isolation and characterization of new phage vB_CtuP_A24 and application to control Cronobacter spp. in infant milk formula and lettuce
    FI129085B|2021-06-30|Improved methods and culture media for production, quantification and isolation of bacteriophages infecting Flavobacterium columnare
    Hu et al.2021|Siphoviridae phage PH669 capable of lysing some strains of O3 and O4 serotypes in Vibrio parahaemolyticus
    CN113201501A|2021-08-03|Vibrio bacteriophage with cross-species lysis capacity and application thereof
    Zeng et al.2021|Novel phage vB_CtuP_B1 for controlling Cronobacter malonaticus and Cronobacter turicensis in ready-to-eat lettuce and powered infant formula
    Li et al.2020|Characterization and whole-genome sequencing of broad-host-range Salmonella-specific bacteriophages for bio-control
    Kawato et al.2020|Isolation and characterisation of an ISKNV-genotype megalocytivirus from imported angelfish Pterophyllum scalare
    CN110846283A|2020-02-28|Escherichia coli bacteriophage with wide lysis spectrum, and composition, kit and application thereof
    Li et al.2021|Isolation and characterization of broad host-range of bacteriophages infecting Cronobacter sakazakii and its biocontrol potential in dairy products
    WO2007128348A1|2007-11-15|Compositions comprising lytic enzymes of bacteriophages for treating bacterial infections
    Kawato et al.2021|Isolation and characterization of hirame aquareovirus |: A new Aquareovirus isolated from diseased hirame Paralichthys olivaceus
    同族专利:
    公开号 | 公开日
    EP3746550A1|2020-12-09|
    FI129085B|2021-06-30|
    WO2019150003A1|2019-08-08|
    US20210047625A1|2021-02-18|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US11260089B2|2014-11-19|2022-03-01|San Diego State University Foundation|Products of manufacture comprising bacteriophages|
    法律状态:
    2021-06-30| FG| Patent granted|Ref document number: 129085 Country of ref document: FI Kind code of ref document: B |
    优先权:
    申请号 | 申请日 | 专利标题
    FI20185086A|FI129085B|2018-01-31|2018-01-31|Improved methods and culture media for production, quantification and isolation of bacteriophages infecting Flavobacterium columnare|FI20185086A| FI129085B|2018-01-31|2018-01-31|Improved methods and culture media for production, quantification and isolation of bacteriophages infecting Flavobacterium columnare|
    PCT/FI2019/050073| WO2019150003A1|2018-01-31|2019-01-31|Improved methods and culture media for production, quantification and isolation of bacteriophages|
    US16/966,472| US20210047625A1|2018-01-31|2019-01-31|Improved methods and culture media for production, quantification and isolation of bacteriophages|
    EP19707851.2A| EP3746550A1|2018-01-31|2019-01-31|Improved methods and culture media for production, quantification and isolation of bacteriophages|
    [返回顶部]